Noxopharm is also part of a St***head ASX biotech video...

Noxopharm is also part of a St***head ASX biotech video conference featured today (available on demand).

In his 10 minute presentation, Graeme Kelly says that data from the Covid trial is currently being reviewed and that results are expected to be released “over the next month or so.”

On the subject of Pharmorage, he says that Hudson Institute has made such considerable progress on its STING inhibitor work that he believes that it is now at the leading edge in this new area of drug development. The Pharmorage STING inhibitor program is targeting chronic inflammatory and autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and motor neurone disease.